2.26
-0.19 (-7.79%)
| Penutupan Terdahulu | 2.45 |
| Buka | 2.48 |
| Jumlah Dagangan | 52,474 |
| Purata Dagangan (3B) | 53,275 |
| Modal Pasaran | 304,370,016 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| Margin Keuntungan | -176.49% |
| Margin Operasi (TTM) | -245.76% |
| EPS Cair (TTM) | -2.30 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6,798.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.00% |
| Nisbah Semasa (MRQ) | 4.18 |
| Aliran Tunai Operasi (OCF TTM) | -334.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -184.76 M |
| Pulangan Atas Aset (ROA TTM) | -27.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (GB) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | IOVANCE BIOTHERAPEUTICS INC IOV | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -1.5 |
| Purata | -0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC IOV | 304 M | - | - | - |
| RELIEF THERAPEUTICS HOLDING SA | 2 B | - | - | 1.08 |
| IDORSIA LTD IDORSIA N ORD SHS | 1 B | - | - | - |
| OXFORD NANOPORE TECHNOLOGIES PL | 1 B | - | - | 2.30 |
| PURETECH HEALTH PLC ORD 1P | 292 M | - | 9.31 | 1.07 |
| FARON PHARMACEUTICALS OY ORD NP | 231 M | - | - | 165.73 |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.35% |
| % Dimiliki oleh Institusi | 81.25% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |